特应性皮炎患者使用度普利尤单抗的银屑病风险
结果显示度普利尤单抗组3年累积银屑病发病率高于对照组(2.86% vs 1.79%;P < .001),风险比HR为1.58(95%CI 1.25-1.99),需伤害人数为94。
要点
- 度普利尤单抗组3年银屑病累积发病率2.86%,高于对照组1.79%。
- 度普利尤单抗与银屑病风险升高相关(HR 1.58;95%CI 1.25-1.99)。
- 需伤害人数为94,绝对风险增幅有限,需权衡疗效。
核心结论
- 特应性皮炎患者使用度普利尤单抗较其他系统药物有更高的银屑病相对风险。
- 需伤害人数为94,绝对风险可能有限临床意义,应权衡度普利尤单抗治疗特应性皮炎的既定疗效。
研究设计与样本
- 基于TriNetX全球协作网络的群体回顾性队列研究,随访3年,分析完成于2024年10月19日。
- 按年龄、性别、种族、合并症、实验室指标和既往用药进行1:1倾向评分匹配,匹配后每队列9860例。
主要发现
- 度普利尤单抗组3年累积银屑病发病率高于对照组(2.86% vs 1.79%;P < .001)。
- 度普利尤单抗队列银屑病风险增加(HR 1.58;95%CI 1.25-1.99),银屑病关节炎风险不显著(HR 1.97;95%CI 0.75-5.18)。
- 无特应性合并症亚组(HR 1.42;95%CI 1.06-1.89)及预处理IgE低于0.048 mg/dL亚组(HR 1.59;95%CI 1.26-2.01)也观察到风险增加。
- 在无特应性皮炎的哮喘患者中验证支持该关联(HR 2.13;95%CI 1.38-3.31)。
关键数值与推荐
- 度普利尤单抗对比其他系统药物(皮质类固醇、甲氨蝶呤、环孢素、硫唑嘌呤或吗替麦考酚酯)。
- 主要结局为 incident psoriasis(新发银屑病),采用Kaplan-Meier曲线评估累积发病率,Cox回归评估风险。
- 需伤害人数为94。
临床怎么用
- 对特应性皮炎患者处方度普利尤单抗时,应知晓银屑病风险相对升高但绝对风险有限。
- 需结合度普利尤单抗治疗特应性皮炎的既定疗效,个体化权衡获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with atopic dermatitis (AD) have been reported to develop psoriasis during dupilumab treatment. Whether this represents a true association or an incidental event remains unclear. OBJECTIVE: To compare psoriasis risk in patients with AD who are prescribed dupilumab vs other systemic agents. DESIGN, SETTING, AND PARTICIPANTS: This population-based retrospective cohort study with 3-year follow-up, with analyses completed on October 19, 2024, included 214 430 adult patients with AD from the TriNetX Global Collaborative Network. Individuals newly prescribed dupilumab (dupilumab cohort) and those newly prescribed the other systemic agents without dupilumab exposure (control cohort) were included. Propensity score matching at a 1:1 ratio based on age, sex, race, comorbidities, laboratory measurements, and prior medications was conducted. EXPOSURES: Dupilumab vs the other systemic agents (corticosteroids, methotrexate, cyclosporine, azathioprine, or mycophenolate mofetil). MAIN OUTCOMES AND MEASURES: The primary outcome was incident psoriasis. Cumulative incidence was assessed using Kaplan-Meier plots and risks via Cox regression. RESULTS: After matching, each cohort comprised 9860 patients, with 10 891 female individuals (55.2%), a mean (SD) age of 44.8 (20.3) years, 3582 African American or Black individuals (18.2%), 2004 Asian individuals (10.2%), and 9901 White individuals (50.2%). The 3-year cumulative psoriasis incidence was higher in the dupilumab cohort than the control cohort (2.86% vs 1.79%; P < .001). The number needed to harm for psoriasis was 94 for dupilumab vs the other systemic agents. The dupilumab cohort showed an increased risk for psoriasis (hazard ratio [HR], 1.58; 95% CI, 1.25-1.99), although the risk for psoriatic arthritis was not significant (HR, 1.97; 95% CI, 0.75-5.18). This increased risk was also observed in various AD subgroups, including those without atopic comorbidities (HR, 1.42; 95% CI, 1.06-1.89) or with pretreatment immunoglobulin E levels less than 0.048 mg/dL (to convert to mg/L, multiply by 10; HR, 1.59; 95% CI, 1.26-2.01). The association between dupilumab and psoriasis was further supported by validation in patients with asthma without AD (HR, 2.13; 95% CI, 1.38-3.31). CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that patients with AD who were prescribed dupilumab exhibited a higher relative risk of developing psoriasis compared with those receiving other systemic agents. Given an estimated number needed to harm of 94, the absolute risk may have limited clinical relevance and should be weighed against dupilumab's established efficacy in treating AD.
引用
- Lin TL, Fan YH, Fan KS, et al. Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab. JAMA Dermatol. 2025. PMID: 40531497. doi:10.1001/jamadermatol.2025.1578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。